Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Shares of HIMS stock opened at $36.01 on Thursday. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market capitalization of $8.00 billion, a price-to ...

More than 90 countries do not have laws mandating equal pay for equal work, while dozens of others prohibit women from working in certain industries, such as construction or manufacturing.

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to "simplify its (company's ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

Semaglutide is no longer in shortage, per the Food and Drug Administration. Hims & Hers had been relying on offering a compounded version to its patients. The stock trades at a high premium which ...

March 7 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being ...

Shares of Hims & Hers Health (HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its GLP-1 weight-loss drug Wegovy by more than half. The move obliterates ...

The Navy earlier brought in a barge and crane to support its salvage work of the wrecked jet. That heavy equipment was removed from the site Sunday. “The recovery team conducted a thorough ...